TME Pharma 
Welcome,         Profile    Billing    Logout  
 3 Products   36 Diseases  3 Products   2 Trials   251 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
olaptesed pegol (NOX-A12) / TME Pharma
2021-001963-25: A clinical study to investigate how a new drug called Olaptesed Pegol (NOX-A12) works in patients with microsatellite-stable metastatic pancreatic cancer when used in combination with other drugs (i.e. Pembrolizumab and Nanoliposomal Irinotecan/5-FU/Leucovorin or Gemcitabine/nab-Paclitaxel). Étude clinique visant à évaluer comment un nouveau médicament appelé olaptesed pégol (NOX A12) agit chez des patients atteints de cancer pancréatique métastatique avec microsatellites stables lorsqu’il est utilisé en association avec d’autres médicaments (à savoir le pembrolizumab et la combinaison irinotécan nanoliposomale/5-FU/leucovorine ou la combinaison gemcitabine/nab-paclitaxel)

Not yet recruiting
2
68
Europe
Olaptesed Pegol, Pembrolizumab, NOX-A12, MK-3475, Concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion
NOXXON Pharma AG, NOXXON Pharma AG
Pancreatic cancer cancer du pancréas, Pancreatic cancer cancer du pancréas, Diseases [C] - Cancer [C04]
 
 
OPTIMUS, NCT04901741: Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer

Not yet recruiting
2
60
NA
Olaptesed pegol, NOX-A12, Pembrolizumab, KEYTRUDA®
TME Pharma AG, Merck Sharp & Dohme LLC
Metastatic Pancreatic Cancer
10/27
10/28
2018-004064-62: Glioblastoma treatment with irradiation and olaptesed pegol in unmethylated patients Behandlung des Glioblastoms mit Bestrahlung und Olaptesed Pegol in unmethylierten Patienten

Not yet recruiting
1/2
27
Europe
Olaptesed pegol, MVASI 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, NOX-A12, Concentrate for solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion
TME Pharma AG, TME Pharma AG
glioblastoma Glioblastom, glioblastoma Glioblastom, Diseases [C] - Cancer [C04]
 
 
GLORIA, NCT04121455 / 2018-004064-62: Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients

Active, not recruiting
1/2
117
Europe
Olaptesed pegol, NOX-A12, Radiotherapy, Bevacizumab, Pembrolizumab, KEYTRUDA, Temozolomide (TMZ)
TME Pharma AG, TME Pharma AG
Glioblastoma
12/28
12/28
NOX-D20 / TME Pharma
No trials found
NOX-S93 / TME Pharma
No trials found
NOX-G15 / TME Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
olaptesed pegol (NOX-A12) / TME Pharma
2021-001963-25: A clinical study to investigate how a new drug called Olaptesed Pegol (NOX-A12) works in patients with microsatellite-stable metastatic pancreatic cancer when used in combination with other drugs (i.e. Pembrolizumab and Nanoliposomal Irinotecan/5-FU/Leucovorin or Gemcitabine/nab-Paclitaxel). Étude clinique visant à évaluer comment un nouveau médicament appelé olaptesed pégol (NOX A12) agit chez des patients atteints de cancer pancréatique métastatique avec microsatellites stables lorsqu’il est utilisé en association avec d’autres médicaments (à savoir le pembrolizumab et la combinaison irinotécan nanoliposomale/5-FU/leucovorine ou la combinaison gemcitabine/nab-paclitaxel)

Not yet recruiting
2
68
Europe
Olaptesed Pegol, Pembrolizumab, NOX-A12, MK-3475, Concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion
NOXXON Pharma AG, NOXXON Pharma AG
Pancreatic cancer cancer du pancréas, Pancreatic cancer cancer du pancréas, Diseases [C] - Cancer [C04]
 
 
OPTIMUS, NCT04901741: Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer

Not yet recruiting
2
60
NA
Olaptesed pegol, NOX-A12, Pembrolizumab, KEYTRUDA®
TME Pharma AG, Merck Sharp & Dohme LLC
Metastatic Pancreatic Cancer
10/27
10/28
2018-004064-62: Glioblastoma treatment with irradiation and olaptesed pegol in unmethylated patients Behandlung des Glioblastoms mit Bestrahlung und Olaptesed Pegol in unmethylierten Patienten

Not yet recruiting
1/2
27
Europe
Olaptesed pegol, MVASI 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, NOX-A12, Concentrate for solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion
TME Pharma AG, TME Pharma AG
glioblastoma Glioblastom, glioblastoma Glioblastom, Diseases [C] - Cancer [C04]
 
 
GLORIA, NCT04121455 / 2018-004064-62: Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients

Active, not recruiting
1/2
117
Europe
Olaptesed pegol, NOX-A12, Radiotherapy, Bevacizumab, Pembrolizumab, KEYTRUDA, Temozolomide (TMZ)
TME Pharma AG, TME Pharma AG
Glioblastoma
12/28
12/28
NOX-D20 / TME Pharma
No trials found
NOX-S93 / TME Pharma
No trials found
NOX-G15 / TME Pharma
No trials found

Download Options